144.10
price up icon2.64%   3.70
after-market Dopo l'orario di chiusura: 144.10
loading
Precedente Chiudi:
$140.40
Aprire:
$140.76
Volume 24 ore:
1.23M
Relative Volume:
1.39
Capitalizzazione di mercato:
$14.29B
Reddito:
$2.41B
Utile/perdita netta:
$305.80M
Rapporto P/E:
48.85
EPS:
2.95
Flusso di cassa netto:
$492.20M
1 W Prestazione:
+3.22%
1M Prestazione:
+12.24%
6M Prestazione:
+26.57%
1 anno Prestazione:
+18.88%
Intervallo 1D:
Value
$136.49
$145.79
Intervallo di 1 settimana:
Value
$135.61
$145.79
Portata 52W:
Value
$84.23
$154.61

Neurocrine Biosciences Inc Stock (NBIX) Company Profile

Name
Nome
Neurocrine Biosciences Inc
Name
Telefono
(858) 617-7600
Name
Indirizzo
6027 EDGEWOOD BEND COURT, SAN DIEGO, CA
Name
Dipendente
1,800
Name
Cinguettio
Name
Prossima data di guadagno
2024-10-30
Name
Ultimi documenti SEC
Name
NBIX's Discussions on Twitter

Confronta NBIX con altri titoli

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
Drug Manufacturers - Specialty & Generic icon
NBIX
Neurocrine Biosciences Inc
144.10 13.93B 2.41B 305.80M 492.20M 2.95
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
153.32 67.90B 9.39B 2.62B 2.22B 5.81
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
15.40 48.29B 29.96B 957.25M 4.77B 0.304
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.80 44.04B 14.26B 1.98B 2.47B 0.4347
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
18.95 21.20B 16.70B -157.13M 1.19B -0.155
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
400.52 17.21B 2.99B 1.21B 1.13B 25.06

Neurocrine Biosciences Inc Stock (NBIX) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2025-07-21 Iniziato Truist Buy
2025-07-10 Iniziato Goldman Buy
2025-04-15 Aggiornamento Needham Hold → Buy
2025-04-14 Aggiornamento RBC Capital Mkts Sector Perform → Outperform
2025-02-11 Iniziato Deutsche Bank Hold
2024-10-10 Ripresa Raymond James Outperform
2024-08-29 Aggiornamento Piper Sandler Neutral → Overweight
2024-04-24 Aggiornamento Wells Fargo Equal Weight → Overweight
2023-12-13 Ripresa Citigroup Neutral
2023-12-12 Iniziato Deutsche Bank Buy
2023-10-24 Ripresa Cantor Fitzgerald Overweight
2023-08-21 Reiterato Mizuho Neutral
2023-07-24 Aggiornamento SVB Securities Market Perform → Outperform
2023-07-06 Aggiornamento BMO Capital Markets Underperform → Market Perform
2023-05-04 Aggiornamento Guggenheim Neutral → Buy
2023-03-30 Aggiornamento Canaccord Genuity Hold → Buy
2023-03-03 Aggiornamento Evercore ISI In-line → Outperform
2023-02-03 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2022-11-14 Downgrade Evercore ISI Outperform → In-line
2022-10-11 Iniziato UBS Buy
2022-09-26 Iniziato Wells Fargo Equal Weight
2022-06-06 Ripresa Jefferies Buy
2022-03-03 Downgrade Piper Sandler Overweight → Neutral
2022-02-25 Aggiornamento Goldman Neutral → Buy
2022-01-18 Downgrade RBC Capital Mkts Outperform → Sector Perform
2021-11-19 Iniziato BMO Capital Markets Underperform
2021-11-17 Aggiornamento JP Morgan Neutral → Overweight
2021-10-14 Downgrade Morgan Stanley Overweight → Equal-Weight
2021-09-23 Ripresa Needham Hold
2021-08-06 Downgrade Canaccord Genuity Buy → Hold
2021-05-18 Ripresa Goldman Neutral
2021-05-06 Aggiornamento Barclays Equal Weight → Overweight
2021-02-02 Iniziato Raymond James Outperform
2020-09-30 Iniziato The Benchmark Company Hold
2020-08-04 Downgrade JP Morgan Overweight → Neutral
2020-06-29 Downgrade Goldman Buy → Neutral
2020-06-09 Iniziato Wedbush Outperform
2020-03-06 Iniziato Citigroup Buy
2020-02-27 Iniziato Barclays Equal Weight
2020-02-24 Iniziato William Blair Outperform
2020-02-06 Iniziato Mizuho Neutral
2020-02-05 Reiterato H.C. Wainwright Buy
2019-12-13 Downgrade Credit Suisse Outperform → Neutral
2019-08-07 Iniziato RBC Capital Mkts Outperform
2019-07-16 Iniziato Oppenheimer Outperform
2019-06-05 Iniziato Guggenheim Neutral
2019-05-21 Iniziato Credit Suisse Outperform
2019-04-22 Aggiornamento JP Morgan Neutral → Overweight
2019-04-12 Iniziato Evercore ISI Outperform
2019-02-06 Reiterato BofA/Merrill Buy
2019-01-23 Downgrade JP Morgan Overweight → Neutral
2018-12-13 Iniziato Goldman Buy
2018-11-21 Iniziato Canaccord Genuity Buy
Mostra tutto

Neurocrine Biosciences Inc Borsa (NBIX) Ultime notizie

pulisher
Sep 06, 2025

Neurocrine Biosciences Inc. recovery potential after sell offJuly 2025 Momentum & Community Consensus Picks - Newser

Sep 06, 2025
pulisher
Sep 06, 2025

Tick level data insight on Neurocrine Biosciences Inc. volatilityLong Setup & Entry Point Confirmation Signals - Newser

Sep 06, 2025
pulisher
Sep 06, 2025

Is Neurocrine Biosciences Inc. benefiting from interest rate changesEarnings Overview Summary & Low Risk Entry Point Tips - خودرو بانک

Sep 06, 2025
pulisher
Sep 05, 2025

Can Neurocrine Biosciences Inc. generate free cash flowJuly 2025 Closing Moves & Accurate Entry/Exit Alerts - خودرو بانک

Sep 05, 2025
pulisher
Sep 05, 2025

Does Neurocrine Biosciences Inc. fit your quant trading modelJuly 2025 Macro Moves & Safe Entry Momentum Tips - Newser

Sep 05, 2025
pulisher
Sep 05, 2025

Neurocrine Biosciences: RBC Capital maintains Outperform, raises PT to $149. - AInvest

Sep 05, 2025
pulisher
Sep 05, 2025

RBC Raises Price Target on Neurocrine Biosciences to $149 From $144, Keeps Outperform Rating - MarketScreener

Sep 05, 2025
pulisher
Sep 05, 2025

What’s next for Neurocrine Biosciences Inc. stock priceWeekly Profit Summary & Reliable Intraday Trade Alerts - Newser

Sep 05, 2025
pulisher
Sep 04, 2025

Will Neurocrine Biosciences Inc. benefit from current market trendsMarket Growth Review & Weekly Consistent Profit Watchlists - خودرو بانک

Sep 04, 2025
pulisher
Sep 04, 2025

Will Neurocrine Biosciences Inc. price bounce be sustainable2025 Key Lessons & Long-Term Capital Growth Strategies - Newser

Sep 04, 2025
pulisher
Sep 04, 2025

Is Neurocrine Biosciences Inc. a cyclical or defensive stockJuly 2025 Breakouts & Weekly Return Optimization Alerts - خودرو بانک

Sep 04, 2025
pulisher
Sep 04, 2025

Will Neurocrine Biosciences Inc. stock go up soonJuly 2025 Volume & Community Consensus Picks - Newser

Sep 04, 2025
pulisher
Sep 04, 2025

Neurocrine at Cantor Global Healthcare Conference: Strategic Insights on Growth - Investing.com Canada

Sep 04, 2025
pulisher
Sep 04, 2025

Neurocrine Biosciences Inc. stock retracement – recovery analysis2025 Stock Rankings & AI Forecasted Stock Moves - Newser

Sep 04, 2025
pulisher
Sep 04, 2025

What are Neurocrine Biosciences Inc.’s growth leversPortfolio Gains Summary & AI Powered Buy and Sell Recommendations - خودرو بانک

Sep 04, 2025
pulisher
Sep 04, 2025

What’s the recovery path for long term holders of Neurocrine Biosciences Inc.July 2025 Analyst Calls & Intraday High Probability Setup Alerts - Newser

Sep 04, 2025
pulisher
Sep 03, 2025

Can Neurocrine Biosciences Inc. hit a new high this monthPortfolio Return Summary & Safe Capital Growth Stock Tips - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Does Neurocrine Biosciences Inc. have pricing powerJuly 2025 Update & Fast Momentum Stock Entry Tips - خودرو بانک

Sep 03, 2025
pulisher
Sep 03, 2025

Neurocrine Biosciences Shares Dip 4.09% on Strong Volume Surge to 478th Rank Amid Q2 Earnings Boost - AInvest

Sep 03, 2025
pulisher
Sep 03, 2025

Neurocrine Biosciences' Strategic Position in the CNS Therapeutics Market - AInvest

Sep 03, 2025
pulisher
Sep 03, 2025

Transcript : Neurocrine Biosciences, Inc. Presents at Cantor Global Healthcare Conference 2025, Sep-03-2025 01 - MarketScreener

Sep 03, 2025
pulisher
Sep 03, 2025

Does Neurocrine Biosciences Inc. qualify in momentum factor screeningJuly 2025 Big Picture & Stepwise Entry and Exit Trade Signals - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Endometriosis Pain Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight by DelveInsight | Organon, Ironwood Pharma, Mitsubishi Tanabe Pharma Corp, AbbVie/Neurocrine - Barchart.com

Sep 03, 2025
pulisher
Sep 03, 2025

What to expect from Neurocrine Biosciences Inc. in the next 30 daysJuly 2025 Final Week & Accurate Buy Signal Alerts - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Is a relief rally coming for Neurocrine Biosciences Inc. holdersMarket Performance Recap & Breakout Confirmation Alerts - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Will Neurocrine Biosciences Inc. stock recover after recent dropBull Run & Weekly Top Gainers Trade List - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Risk vs reward if holding onto Neurocrine Biosciences Inc.July 2025 Volume & Trade Opportunity Analysis Reports - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Custom watchlist performance reports with Neurocrine Biosciences Inc.Portfolio Profit Report & Real-Time Buy Zone Alerts - Newser

Sep 03, 2025
pulisher
Sep 03, 2025

Neurocrine Biosciences Inc. stock trendline breakdownIndex Update & Free Technical Confirmation Trade Alerts - Newser

Sep 03, 2025
pulisher
Sep 02, 2025

Long term hold vs stop loss in Neurocrine Biosciences Inc.2025 Volatility Report & Real-Time Chart Pattern Alerts - Newser

Sep 02, 2025
pulisher
Sep 02, 2025

Will Neurocrine Biosciences Inc. stock hit new highs in YEARQuarterly Market Review & Stock Market Timing Techniques - خودرو بانک

Sep 02, 2025
pulisher
Sep 02, 2025

Is Neurocrine Biosciences Inc. showing signs of accumulation2025 Top Gainers & Fast Gaining Stock Reports - Newser

Sep 02, 2025
pulisher
Sep 02, 2025

Is Neurocrine Biosciences Inc. being accumulated by smart moneyJuly 2025 Levels & Fast Entry and Exit Trade Plans - خودرو بانک

Sep 02, 2025
pulisher
Sep 02, 2025

Technical Bounce Expected in Neurocrine Biosciences Inc. Next Week getLinesFromResByArray error: size == 0 - thegnnews.com

Sep 02, 2025
pulisher
Sep 02, 2025

Neurocrine Biosciences, Inc. (NBIX) Beats Estimates on Neurology Drug Demand, Expands Payer Access - Yahoo Finance

Sep 02, 2025
pulisher
Sep 01, 2025

Is Neurocrine Biosciences Inc. forming a reversal patternVolume Spike & Reliable Price Action Trade Plans - Newser

Sep 01, 2025
pulisher
Sep 01, 2025

Understanding Neurocrine Biosciences Inc.’s price movement2025 Technical Patterns & High Yield Stock Recommendations - Newser

Sep 01, 2025
pulisher
Sep 01, 2025

Real time social sentiment graph for Neurocrine Biosciences Inc.Jobs Report & Weekly Breakout Opportunity Watchlist - Newser

Sep 01, 2025
pulisher
Aug 31, 2025

Tools to monitor Neurocrine Biosciences Inc. recovery probabilityTrade Ideas & AI Enhanced Trading Signals - Newser

Aug 31, 2025
pulisher
Aug 31, 2025

Historical volatility pattern of Neurocrine Biosciences Inc. visualizedMarket Performance Recap & Low Drawdown Investment Ideas - Newser

Aug 31, 2025
pulisher
Aug 31, 2025

Will Neurocrine Biosciences Inc. outperform small cap indexes2025 Historical Comparison & Real-Time Volume Trigger Notifications - 선데이타임즈

Aug 31, 2025
pulisher
Aug 31, 2025

How Neurocrine Biosciences Inc. stock performs during market volatilityMarket Growth Summary & Weekly Setup with High ROI Potential - Newser

Aug 31, 2025
pulisher
Aug 31, 2025

How to integrate Neurocrine Biosciences Inc. into portfolio analysis toolsEarnings Miss & Technical Entry and Exit Alerts - Newser

Aug 31, 2025
pulisher
Aug 31, 2025

Ranking Neurocrine Biosciences Inc. among high performing stocks via tools2025 Macro Impact & Verified Momentum Stock Ideas - Newser

Aug 31, 2025
pulisher
Aug 31, 2025

What Fibonacci levels say about Neurocrine Biosciences Inc. reboundProduct Launch & Verified High Yield Trade Plans - Newser

Aug 31, 2025

Neurocrine Biosciences Inc Azioni (NBIX) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading

Neurocrine Biosciences Inc Azioni (NBIX) insider trading

Commercio interno Relazione Data Transazione Costo #Azioni Valore ($) #Azioni Totale
GORMAN KEVIN CHARLES
Director
Aug 07 '25
Sale
126.41
106,322
13,440,281
514,596
$10.50
price up icon 1.65%
drug_manufacturers_specialty_generic RDY
$14.34
price up icon 1.34%
$400.52
price up icon 5.27%
$18.43
price up icon 5.50%
$18.95
price up icon 2.54%
Capitalizzazione:     |  Volume (24 ore):